Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow
Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m
Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer
Apellis' share price came under pressure today after it revealed new details about a rare but serious side effect with its recently-approved Syfovre therapy for eye diseas
Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.